Background Non-vitamin K antagonist oral anticoagulants (NOACs) have been proposed as
an alternative to vitamin K antagonists (VKA) for atrial fibrillation (AF) patients. Some studies …

Nonvitamin K antagonist oral anticoagulants (NOACs) have been proposed as an
alternative to vitamin K antagonists in atrial fibrillation (AF) patients but the comparative …

Atrial fibrillation (AF) patients treated with well-controlled vitamin K antagonists (VKAs) may
benefit less from non-vitamin K antagonist oral anticoagulants (NOACs) because they are …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) require dose reductions
according to patient or clinical factors for patients with atrial fibrillation (AF). In this meta …

Background We evaluated the dose-dependent efficacy, safety, and all-cause mortality of
non-vitamin K antagonist oral anticoagulants (NOACs) in “atrial fibrillation (AF) patients who …

Background Current guidelines recommend non-vitamin‑K oral anticoagulants (NOACs) as
the first-choice therapy for stroke prevention in patients with atrial fibrillation (AF). The use of …

Non-vitamin K antagonist oral anticoagulants (NOACs) were developed and approved as
substitutes for vitamin K antagonists (VKAs)[1–3]. NOACs have become the preferred …

Vitamin K antagonists (VKAs), together with newer oral anticoagulants (NOACs) such as
dabigatran, rivaroxaban, or apixaban, reduce the risk of stroke in patients with atrial …

Objective There has been limited systematic evaluation of outcomes and drivers of
inappropriate non-vitamin K antagonist oral anticoagulants (NOACs) dosing among patients …

Anticoagulation is fundamental in the management of patients with atrial fibrillation (AF). The
study aims to provide a comparative review of the major phase III randomized clinical trials …